HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy.

AbstractUNLABELLED:
Scintigraphy with somatostatin analogs is a sensitive method for the staging and therapeutic management of patients with endocrine gastroenteropancreatic (GEP) tumors. The aim of this study was to compare prospectively somatostatin receptor scintigraphy (SRS) using 111n-pentetreotide with bone scintigraphy using 99mTc-hydroxymethylene diphosphonate for the detection of bone metastases.
METHODS:
One-hundred-forty-five patients with proven endocrine GEP tumors were investigated. Patients were classified according to the presence of bone metastases as indicated by CT, MRI or histologic data. Group I included 19 patients with confirmed bone metastases, and group II included 126 patients without bone metastases.
RESULTS:
In group I, SRS was positive in all 19 patients with bone metastases, and bone scintigraphy was positive in 17 patients. Bone metastases were found to occur predominantly in patients with liver metastases. In group 11, 5 patients had recent bone surgery for fracture or arthritis. SRS showed bone uptake in 4 of these patients, and bone scanning showed abnormal uptake in 5. In 7 of the remaining 121 group II patients, SRS was negative and bone scanning showed abnormal bone uptake suggesting bone metastases. The detection of bone metastases was of major prognostic value, because 42% of group 1 patients died during a 2-y follow-up.
CONCLUSION:
In patients with GEP tumors, the accuracy of SRS appears to be similar to that of bone scintigraphy for the detection of bone metastases.
AuthorsR Lebtahi, G Cadiot, N Delahaye, R Genin, D Daou, M C Peker, D Chosidow, M Faraggi, M Mignon, D Le Guludec
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 40 Issue 10 Pg. 1602-8 (Oct 1999) ISSN: 0161-5505 [Print] United States
PMID10520698 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Indium Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • SDZ 215-811
  • Somatostatin
  • technetium Tc 99m hydroxymethylene diphosphonate
  • Pentetic Acid
  • pentetreotide
  • Octreotide
  • Technetium Tc 99m Medronate
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms (diagnostic imaging, secondary)
  • Carcinoid Tumor (diagnostic imaging)
  • Digestive System Neoplasms (diagnostic imaging, metabolism)
  • Female
  • Humans
  • Indium Radioisotopes
  • Male
  • Middle Aged
  • Octreotide (analogs & derivatives)
  • Pentetic Acid (analogs & derivatives)
  • Prospective Studies
  • Radionuclide Imaging
  • Radiopharmaceuticals
  • Receptors, Somatostatin (metabolism)
  • Somatostatin (analogs & derivatives)
  • Technetium Tc 99m Medronate (analogs & derivatives)
  • Zollinger-Ellison Syndrome (diagnostic imaging)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: